Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
Equities
603707
CNE100002WP3
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.22 CNY | -0.49% |
|
-6.14% | -18.53% |
03/06 | US FDA Approves Additional Production Site for King-Friend Biochemical Pharma's Melanoma, Hodgkin's Disease Drug | MT |
28/05 | Hybio Pharmaceutical Gets Nod to Market Ganirelix Acetate Injection | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.53% | 2.71B | |
+52.93% | 803B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.51% | 243B | |
+1.76% | 228B | |
+10.04% | 217B | |
+6.24% | 164B | |
-4.79% | 155B |
- Stock Market
- Equities
- 603707 Stock
- News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
- NKFPharma's Unit Gets FDA's Nod to Market Eptifibatide Injection in US